WANBURYNSEWanbury Limited· PharmaceuticalsMinimalNeutral
Announced Fri, 24 Apr · 18:17 IST

Wanbury Limited has informed the Exchange about General Updates

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.4%1-day move
₹258.50
prior close
₹262.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4+0.2+0.8+0.8+0.4-0.2-1.4-1.4-2.1-1.7-0.2+16.1+9.8+27.0
Up moveDown movePending
AI summary

Wanbury Limited filed its annual Secretarial Compliance Report for FY ended March 2026. The report identifies one current non-compliance: a delayed submission of Shareholding Pattern for Q2 FY2025-26 (quarter ended September 30, 2025), which attracted a fine of Rs. 42,480 from BSE, subsequently paid via NEFT on November 27, 2025. The report also details resolution of prior period non-compliances from FY 2024-25, including board composition falling below 6 directors (now restored with new independent director appointments), Audit Committee composition issues (fine of Rs. 335,120 paid), and Nomination & Remuneration Committee issues (fine of Rs. 1,057,280 paid). Total fines from prior period amounted to Rs. 37,99,600. Promoter dematerialization remains at 76.74%, with company in process of completing it. All other compliance areas including secretarial standards, policies, website, insider trading, and related party transactions were found satisfactory.

Likely market impact

The company has cleared most prior governance non-compliances with fines paid, though one late filing fine was incurred in the current period. Promoter demat progress and any future compliance lapses remain watch points for investors.